The novel local-acting ileal bile acid transporter inhibitor elobixibat helps relieve chronic constipation in the short term, with well tolerated safety profile in the long term — supporting the novel approach of increasing intracolonic bile acid concentration for treating chronic constipation, two phase III studies show.
Low-dose aspirin users appear to be at greater risk of lower (LGIB) than upper gastrointestinal bleeding, a study has found. Furthermore, LGIB is associated with higher rates of hospitalization or death within 30 days.
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Supplementation with omega-3 long-chain polyunsaturated fatty acids appears beneficial to patients with nonalcoholic fatty liver disease (NAFLD), producing significant improvements in liver fat content, steatosis score and several cardiometabolic risk factors, according to a systematic review and meta-analysis.
Hepatitis C virus (HCV) treatment may benefit patients with HCV-related hepatocellular carcinoma (HCC) who respond to the initial HCC palliative treatment, suggest the results of a study, adding, however, that treating HCV in HCC patient undergoing noncurative HCC treatment remains debatable.
A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.